Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00323557 · ClinicalTrials.gov registry record · Phase 2
Immuno-Augmentation With GM-CSF of Pneumococcal Vaccine in Chronic Lymphocytic Leukemia Patients
A Phase 2 study, sponsored by M.D. Anderson Cancer Center.
- Completed
- Registry status
- Phase 2
- Development phase
- 39
- Enrollment target
NCT00323557: Completed Phase 2 study, sponsored by M.D. Anderson Cancer Center.
NCT00323557 is a Phase 2 study that has completed, run by M.D. Anderson Cancer Center. The registered enrollment target is 39 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00323557, a Phase 2 study, has completed, sponsored by M.D. Anderson Cancer Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 39 participants
- Enrollment target
Study Summary
The goal of this clinical research study is to see if Leukine(R) (sargramostim) improves the effectiveness of the pneumococcal vaccine, a medicine used to prevent pneumococcal pneumonia, in patients with chronic lymphocytic leukemia (CLL).
Interventions
- BIOLOGICAL Pneumococcal Vaccine
- DRUG Sargramostim (GM-CSF)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 39 participants |
| Start Date | 2004-06 |
| Est. Completion | 2011-05 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00323557
The ClinicalTrials.gov registry entry for NCT00323557 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 39 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Pneumococcal Vaccine is the first listed.
NCT00323557 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00323557 about?
NCT00323557 is a clinical study titled "Immuno-Augmentation With GM-CSF of Pneumococcal Vaccine in Chronic Lymphocytic Leukemia Patients". The goal of this clinical research study is to see if Leukine(R) (sargramostim) improves the effectiveness of the pneumococcal vaccine, a medicine used to prevent pneumococcal pneumonia, in patients with chronic lymphocytic leukemia (CLL).
What is the current status of trial NCT00323557?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 39 participants. The study started on 2004-06. Estimated completion is 2011-05.
What interventions are being tested in trial NCT00323557?
The interventions under investigation include: Pneumococcal Vaccine (BIOLOGICAL), Sargramostim (GM-CSF) (DRUG).
Who is sponsoring clinical trial NCT00323557?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.